Bio-Techne Corporation has released a corporate presentation highlighting its focus on purposeful innovation to advance science and medicine. The company, a leader in proteomics for 48 years, outlines its differentiated portfolio that serves high-growth markets. The presentation details their segments and product portfolio, including Protein Sciences, Cell Therapy, Diagnostics, and Spatial Biology. Bio-Techne reported FY2024 revenues of approximately $1.2 billion, with a significant portion derived from consumables. The company operates globally with headquarters in Minneapolis, MN, employing around 3,100 people across 34 worldwide locations. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。